Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Wyeth

Status and phase: Terminated; Phase 1

Conditions: Neoplasms

Treatments: Drug: MST-997

Study type: Interventional

Funder types: Industry

Identifiers

NCT00277836

3161K1-101

Details and patient eligibility

About

MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of malignant solid tumor with measurable disease
• Life expectancy of at least 12 weeks
• ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2

Exclusion criteria

• Recent major surgery, radiation therapy or anti-cancer treatment
• History of any other prior malignancy within last 5 years

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)